Navigation Links
UC Davis discovery offers hope for treating kidney cancer
Date:12/23/2008

Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.

In one of the first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for kidney cancer more effective and better tolerated. The outcome is published in the current issue of Cancer Biology and Therapy.

"Cancer cells are notorious in their ability to rapidly create copies of themselves. While the latest medications slow down that process, they do not tend to be curative and have many side effects," said Robert Weiss, a UC Davis professor of nephrology and chief of nephrology at the Sacramento VA Medical Center. "We wanted to find ways to help make chemotherapeutics as effective as possible at the lowest doses possible."

Newer medications work by destabilizing cancer cells at the DNA level, which reduces their ability to replicate. Knowing that the p21 gene has an important role in restoring cancer cell DNA and potentially circumventing the benefits of those treatments, Weiss sought to identify compounds that could interrupt this pathway.

The team tested thousands of compounds and 12 were found to bind to the recombinant protein p21. Additional tests showed that three of those compounds decreased p21 expression, blocking kidney cancer cells' ability to mend and making them more responsive to DNA-damaging treatments.

"The results are very exciting, especially given how difficult kidney cancer has so far been to treat," Weiss said. "Our work offers hope that in the future these p21 inhibitors can be refined and used in concert with other conventional as well as novel cancer treatments to increase the comfort and life spans of patients with kidney cancer."

For future studies, Weiss will focus on the three candidate compounds to determine the lowest possible concentrations at which they remain effective and to further optimize their anti-cancer properties. He will then test those compounds with standard treatments in animal models and, ultimately, in human trials.

"The goal is to find new approaches to treating a cancer for which few options currently exist and make those approaches available in clinical settings as quickly as possible," he said.


'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Related biology news :

1. UC Davis team refines cancer treatments to reduce potential nerve damage
2. UC Davis researchers exploring gene therapy to fight AIDS
3. UC Davis researchers discover Achilles heel in pancreatic cancer
4. UC Davis researchers discover a key to aggressive breast cancer
5. UC Davis chemical ecologist wins major award
6. UC Davis researchers discover new drug target for inflammatory disease
7. UC Davis researchers define characteristics, treatment options for XXYY syndrome
8. UC Davis researcher leads climate-change discovery
9. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
10. UC Davis researchers discover how HIV turns food-poisoning into lethal infection
11. UC Davis bird-flu expert calls for changes in early-warning system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... Litmus ... an extensive third-party assessment of the company’s security practices has been completed. The ... security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to ...
(Date:8/23/2020)... Texas (PRWEB) , ... August 21, 2020 , ... ... Rigaku Corporation has been published and is now available on the ... crystal X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based in ... into license agreements with Housey Pharma’s HMI subsidiary to gain access to its ... annual Research and Development spending in excess of US $10 billion. , Scientists ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and ... a strategic partnership whereby Catalent will provide support for the development, manufacturing, and ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information ... live webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). ... Specifically, for medical devices, the NMPA has departments dealing with medical device registration (pre-market ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... the life sciences and food industries, is pleased to announce that Charles Galea ... – Business Development. , Charles is an accomplished and results-driven sales executive with ...
Breaking Biology Technology: